Potential therapy for Parkinson’s disease through llama antibodies
A study published today in BMC Biology reports that llama-derived nanobodies – essentially miniature antibodies – might find therapeutic application in… Read more »
Dr. Erwin De Genst & Dr. Marija Iljina
Dr. Erwin De Genst completed his PhD work on the molecular recognition and maturation of camelid heavy-chain antibodies at the Free University of Brussels, Belgium. Afterwards, he moved to the Department of Chemistry at the University of Cambridge on a Marie-Curie and EMBO fellowship and later funded by the Medical Research Council. Here he developed single-domain antibodies (nanobodies) against the proteins human lysozyme and alpha-synuclein, as research tools for the investigation of the origins of systemic amyloidosis and Parkinson's disease. Currently, he is a Post-doctoral research fellow at AstraZeneca in collaboration with the Karolinska Institutet in Stockholm.
Dr. Marija Iljina has recently completed her doctoral degree in the Department of Chemistry at the University of Cambridge, where her research has been focussed on applying single-molecule microscopy techniques to study the aggregation of alpha-synuclein and other proteins implicated in neurodegenerative diseases.
Dr. Marija Iljina has recently completed her doctoral degree in the Department of Chemistry at the University of Cambridge, where her research has been focussed on applying single-molecule microscopy techniques to study the aggregation of alpha-synuclein and other proteins implicated in neurodegenerative diseases.
Latest posts by Dr. Erwin De Genst & Dr. Marija Iljina (see all)